The profile of covid-19 patients with hypertension at siloam dhirga surya hospital from may to november 2020 epifanus arie tanoto1

The Coronavirus Disease 19 (COVID-19) is a highly transmissible and pathogenic viral infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China then spread around the world. According to Huang et al, hypertension is one of the most common comorbid conditions among COVID-19 patients and was linked to more severe infection which require intensive care monitoring. Hypertension associated with COVID-19, likely involves dysregulation of the RAS/ACE2 system due to SARS-CoV-2 infection. This retrospective observational study describes demography of hypertension patient with COVID-19 using total sampling. Data were collected from patient's medical record from May 2020 until November 2020. From 386 COVID-19 patients who were admitted to hospital, there were 70 COVID-19 patients with hypertension (9 patients were excluded). The prevalence of those patients in our study was 15,8 % (male: 55,7%, female: 44,3%). According to age category in JNC VIII, our subjects were divided to 18-59 years (35 patients), 60-79 years (34 patients), 80 years and over (2 patients). The highest systolic and diastolic BP were 213 (mean 148.54) mmHg and 123 (mean 82.75) mmHg. Drug of choice were CCB (35 patients), ARB (32 patients), and CCB/ARB combinations (21 patients). The average length of stay was 15 days. Among 61 patients were admitted, 51 patients were discharged from hospital and 10 patients died. In summary, COVID-19 patients with hypertension need multidisplinary management due to the high prevalence of hypertension in older individuals, preexisting other comorbidities, commonly used antihypertensive medications, and interactions between COVID-19.